New hope for women with multiple pregnancy losses: immune drug added to standard treatment
NCT ID NCT06652113
Summary
This study is testing whether adding hydroxychloroquine (an immune-modulating drug) to standard thyroid medication improves live birth rates in women who have normal thyroid function but carry thyroid antibodies and have experienced multiple unexplained pregnancy losses. Researchers will compare the combination treatment against thyroid medication alone in 796 women across multiple centers. Participants will take their assigned treatment daily starting at least 8 weeks before trying to conceive and continue throughout pregnancy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PREGNANCY LOSS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.